Clinical Trial
doi: 10.1007/BF00616417.
Double blind cross-over study of a new appetite suppressant AN 448
- PMID: 786676
- DOI: 10.1007/BF00616417
Item in Clipboard
Clinical Trial
Double blind cross-over study of a new appetite suppressant AN 448
Eur J Clin Pharmacol.
1975.
Abstract
The effects of a new appetite suppressant, AN 448, and a placebo have been compared in 30 obese individuals using a fully randomized double-blind cross-over design. 1 mg of AN 448 t.i.d. produced a significant degree of appetite suppression and a mean weight loss of more than 4 kg per individual over a 6 week period. Side effects were few and no haematological, renal or hepatic damage was observed.
Similar articles
-
Double-blind evaluation of mazindol in refractory obesity.Br Med J. 1975 Aug 2;3(5978):284. doi: 10.1136/bmj.3.5978.284. Br Med J. 1975. PMID: 1097046 Free PMC article. Clinical Trial. No abstract available.
-
[Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].Rev Med Chil. 1977 Jun;105(6):375-9. Rev Med Chil. 1977. PMID: 331428 Clinical Trial. Spanish. No abstract available.
-
AN 448 Sandoz (Mazindol) in the treatment of obesity.Med J Aust. 1976 Mar 13;1(11):343-5. Med J Aust. 1976. PMID: 775265 Clinical Trial.
-
Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.Am J Clin Nutr. 1992 Jan;55(1 Suppl):199S-202S. doi: 10.1093/ajcn/55.1.199s. Am J Clin Nutr. 1992. PMID: 1728834 Review.
-
Clinical studies with mazindol.Obes Res. 1995 Nov;3 Suppl 4:549S-552S. doi: 10.1002/j.1550-8528.1995.tb00226.x. Obes Res. 1995. PMID: 8697057 Review.
Cited by
-
Some effects of mazindol on the metabolism of monoamines in the rat brain [proceedings].Br J Pharmacol. 1976 Oct;58(2):271P. Br J Pharmacol. 1976. PMID: 974392 Free PMC article. No abstract available.
References
-
- Curr Ther Res Clin Exp. 1969 May;11(5):256-62 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
